Showing posts with label Bydureon. Show all posts
Showing posts with label Bydureon. Show all posts

Tuesday, October 19, 2010

I Think I Give Up On The FDA

With tonight's news of Amylin (Nasdaq: AMLN) getting yet another complete response letter (CRL) from the FDA on Bydureon, I am just about ready to give up on the FDA. Even though Bydureon has shown no particular cardiovascular risk, the FDA has decided to ask for a QT study - a request that is going to take at least a year to fulfill (to say nothing of another six months or so for review).

I would love to know why the FDA did not request this back in the first CRL. I cannot stand conspiracy theorizing, but I am beginning to wonder if the FDA has just decided to abandon its supposed mission of evaluating the safety and efficacy of new drugs in favor of just ruling that any and all new drugs are potentially unsafe and therefore unapprovable.

Although I think Amylin has the capital to endure this delay, and I still believe Bydureon is the best drug in its class, I do not know how anybody can just assume that the drug will get approval. It seems clear to me that the FDA does NOT want to approve this drug and will come up with whatever obstacles are necessary to block it.

By the same token, then, this is bad news for any company looking to get a new compound through the FDA. Maybe Big Pharma can still push some compounds through, but it feels like the little companies do not stand a chance.Good luck, then, to Biodel (Nasdaq: BIOD) and its problematic Phase 3 data on Linjeta - if the FDA will not approve Bydureon, I cannot see how Biodel gets through.

I wonder how long this will go on before somebody decides it is time to audit and investigate the FDA and re-examine its mandate. I appreciate and respect the necessity of protecting the public from unsafe drugs, but allowing unmet medical needs to remain unmet simply because of fanciful fears of possible harm does nobody any good. At this point, I argue that the FDA is abusing its mandate and needs a Congressional slap upside the head to remind it of its obligations to facilitate the introduction of new drugs and devices.

Anyways, I do not wish to turn this into a long-winded rant about the FDA, so I will bring this to a close. This is a major disappointment to Amylin shareholders, but it is not the end of the story yet. I still have some hope that this story will work out, but it is definitely going to take longer than I had hoped.

Disclosure - I own shares of Amylin

Wednesday, July 14, 2010

Avandia Gets A Reprieve?

Apparently the expert panel commissioned by the FDA to evaluate GlaxoSmithKline's (NYSE: GSK) now-controversial diabetes drug Avandia has voted to recommend that the drug stay on the market. The vote, 20-12, is not binding and although the FDA usually does as its panels recommend, they do not always do so - particularly in cases of safety concerns.

As a brief background, Avandia (also known as rosiglitazone), is a gamma PPAR diabetes drug that makes cells more responsive to insulin. Although it is quite effective (reducing HbA1C by 0.5% or more, a nearly 10% improvement in this important diabetes diagnostic marker), some studies have indicated it carries a much higher risk of heart attack and death from cardiac problems than other gamma PPARs or other anti-diabetes drugs in general. The issue has grown with time, precipitating this FDA meeting.

Although Avandia may be allowed to stay on the market, its glory days are almost certainly over. Actos, a rival PPAR drug marketed by Takeda does not seem to have the same risks. Moreover, this whole class has been a sort of pharmaceutical Bermuda Triangle - AstraZeneca, Bristol Myers Squibb, and Daiichi Sankyo have all had serious issues with PPAR drugs they tried to develop, and relatively few compounds are in clinical studies now.

Moreover, there are plenty of other fish in the sea - including GLP-1 analogs (Amylin, Lilly, Roche, Novo Nordisk,  and Glaxo) and DPP-4 inhibitors (Merck) on the market or in late development. Plus, very old drugs like metformin are still reasonably effective and have positive risk-benefit trade-offs.

I am a little surprised to see this result, but as I said, I do not think it will matter too much. Even if the FDA allows the drug to stay on the market, Glaxo is going to have a helluva time driving prescription growth. In the meantime, I have a vested interest here in hoping that Amylin's long-acting GLP-1 analog Bydureon steals the show.

Disclosure - I own shares of Amylin

Brief update: Of the 20 who voted NOT to remove Avandia, 10 want sells restricted and stronger warning labels, 7 want stronger labels but no new restrictions, and three recommended no changes. This breakdown makes me think that further restrictions (at a minimum) are a near-certainty and total withdrawal could still happen. 

Friday, June 18, 2010

Amylin Finally Gets a Break

Sometimes I wonder if Amylin (Nasdaq: AMLN) management if hugged a black cat while standing on a broken mirror underneath a ladder. In other words, if it were not for bad luck, they would have no luck at all (I am waiting for Amylin Pharmaceuticals - The Country Western Album). But in a rare change of pace, they got a little bit of good news due to bad luck at another company.

Roche (RHHBY.PK) announced today that they are going to be delaying the filing of its diabetes drug taspoglutide (licensed from Ipsen) for at least 12 - 18 months to reevaluate its safety. This comes in the wake of news that a Phase 3 study of this GLP-1 analog showed that some patients developed a hypersensitive response with skin and GI problems, but sometimes cardio and respiratory problems as well. Once the drug was stopped, the symptoms went away.

I give a lot of credit to Roche for dealing with this quickly and relatively decisively. The reactions are not too common (apparently less than 1% of patients), but the company is wise to realize that the FDA itself is hypersensitive these days and it is crucial to come to the agency with clean safety data. Moreover, this is generally part of how Roche does business - they are not a group of cowboys that tries to push through questionable data.

For Amylin, this is certainly a break. Amylin just realized clinical data on its once-weekly Bydureon (taspoglutide is always once-weekly) that demonstrates it likely will not be a first-line therapy. That news hit the stock pretty hard, although I do not understand why people thought it would be a first-line option when metformin is still effective, easy to take, and very cheap. Now, though, one of the major potential competitors is on the shelf a bit longer and may carry concerns or even a warning label into the market assuming it gets approval. Better still, for Amylin that is, Roche's drug may require antibody testing and that little extra inconvenience could be enough to alter market share.

Of course, this is also good news for Novo Nordisk (NYSE: NVO) as this company actually has its Victoza long-acting GLP-1 drug on the market.

I still happen to think that Bydureon has a good chance of becoming the top extended-release GLP-1 drug on the market, even though Victoza is benefiting from being the only game in town right now. I think Bydureon gets approved, and I think its edge in clinical performance will drive strong adoption once it is released. But then, I own Amylin stock so that should be expected (if I did not think they were going to "win", I would sell the stock and buy something else).

All in all, this is no reason to sell Roche (and I am certainly thinking about buying on the dip), but maybe a reason to consider buying Amylin if you do not already own it. The third major player, Novo Nordisk, is a great pharmaceutical company in its own right, but perpetually expensive.